---
document_datetime: 2023-12-06 15:21:02
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/amglidia-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: amglidia-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9762272
conversion_datetime: 2025-12-21 16:25:05.766199
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Amglidia

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0017            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                 | 05/12/2023                          |                                             | SmPC and PL                      |           |
| IAIN/0016            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 25/09/2023                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0015             | Update of section 5.1 of the SmPC in order to update information regarding sulphonylurea effects on neurological abnormalities in children and adults with KCNJ11- and ABCC8-related neonatal diabetes based on literature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 25/05/2023   |            | SmPC                   |                                                                                                                                                                                                                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                         | 10/11/2022   | 09/02/2023 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Amglidia in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10690 /202205 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)                                                                                                                                                                                                                                            | 12/01/2023   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IB/0012             | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                          | 06/07/2022   | n/a        |                        |                                                                                                                                                                                                                                                                        |
| PSUSA/10690 /202105 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)                                                                                                                                                                                                                                            | 13/01/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IAIN/0010/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                                               | 25/02/2021   | 16/02/2022 | Annex II and PL        |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| control/testing takes place B.III.1.a.2 - Submission deletion of Ph. Eur. Certificate relevant Ph. Eur. Monograph from an already approved B.III.1.a.2 - Submission deletion of Ph. Eur. Certificate relevant Ph. Eur. Monograph from an already approved B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.c.1 - Change to arrangements and quality Replacement or addition responsible for importation Not including batch control/testing B.II.b.1.a - Replacement   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10690 /202005 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/01/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/10690 /201911 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/06/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| N/0007              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/02/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/10690 /201905 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/01/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0004             | Update of section 4.2 and 5.1 of the SmPC to reconcile posology instructions with the actual use of the product in clinical practice in order to avoid overdosing, to harmonise sections related to 'Dosage adjustments and long-term treatment management' and remove reference to the off-label use of crushed tablets. This update is based on recently published literature, the ISPAD consensus guideline, and in line with the NEOGLI CSR. In addition, the applicant took the opportunity to make editorial corrections. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 04/07/2019 | 03/09/2019 | SmPC and PL | Update based on recently published literature, the ISPAD consensus guideline, and in line with the NEOGLI Clinical Study Report. The SmPC section 4.2 has been updated to reconcile posology instructions with the actual use of the product in clinical practice and to improve clarity and readability. The segment 'Dosage adjustments and long-term management' is initiated by a new paragraph summarising information on observed average daily doses. In the recommendation for blood glucose and HbA1c monitoring after insulin discontinuation it was added that, once insulin independence is achieved and steady state of glibenclamide is reached, capillary blood glucose does no longer need to be daily monitored except in clinical situations at risk of metabolic unbalance. In all cases, HbA1c must be monitored every three months. Reference to the off-label use of crushed tablets was removed. |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                              |            |            |                        | The SmPC section 5.1 has been updated with reference to the success rate, the average doses, and most recent data.   |
|---------------------|--------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------|
| IA/0005             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 16/07/2019 | n/a        |                        |                                                                                                                      |
| PSUSA/10690 /201811 | Periodic Safety Update EU Single assessment - glibenclamide (for centrally authorised products only)         | 14/06/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                    |
| IAIN/0002           | A.1 - Administrative change - Change in the name and/or address of the MAH                                   | 18/12/2018 | 03/09/2019 | SmPC, Labelling and PL |                                                                                                                      |
| N/0001              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)             | 31/07/2018 | 03/09/2019 | Labelling              |                                                                                                                      |